Seite 1 von 15
Artikel Jahr
Klimek L, Uhlig J, Moesges R, Rettig K, Pfaar O: A high polymerized grass pollen extract is efficacious and safe in a randomized double-blind, placebo-controlled study using a novel up-dosing cluster-protocol. Allergy 2014;69: 1629-1638 2014
Richarz U, Gaudig M, Rettig K, Schauble B: Galantamine treatment in outpatients with mild Alzheimer's disease. Acta Neurol Scand. 2014;129(6):382-392 2014
Honecker F, Wedding U, Rettig K, Huschens S, Bokemeyer C, on behalf of the IN-GHO® Advisory Board: Older cancer patients with a body mass index <20 kg/m2 receive less therapy and have higher early mortality rates- results from the IN-GHO® registry. Poster presented at the ASCO Annual Meeting June 1 - 5, 2012, Chicago, Illinois (abstract #98092). 2012
Berek M, Kordon A, Hargarter L, Mattejat F, Slawik L, Rettig K, Schäuble B: Improved functionality, health related quality of life and decreased burden of disease in patients with ADHD treated with OROS(R) MPH: is treatment response different between children and adolescents? Child and Adolescent Psychiatry and Mental Health 2011, 5:26 2011
Hufnagel A, Kowalik A, Rettig K, Schreiner A, Schauble B on behalf of the TOP-GER-11 investigators: Long-term assessment of topiramate for epilepsy - an open-label, single-arm, multicentre, prospective study in a naturalistic setting. Clinical Drug Investigation 2011; 31: 779-790 2011
Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B: Exploring the impact of once-daily Oros® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH. Postgraduate Medicine 2011: 123, 27-38 2011
Möricke R, Rettig K, Bethke TD: Use of Recombinant Human Parathyroid Hormone(1-84) in Patients with Postmenopausal Osteoporosis - A Prospective, Open-Label, Single-Arm, Multicentre, Observational Cohort Study of the Effects of Treatment on Quality of Life and Pain - the PROPOSE Study. Clin Drug In-vestig 2011; 31: 87-99 2011
Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B: Transitioning to OROS® methylphenidate from atomoxetine is effective in children and adolescents with ADHD. Expert Review of Neurotherapeutics 2011, 11, 499-508 2011
Seite 1 von 15